APR 02, 2020 5:40 AM PDT

Diagnosing Cancer: SMOC2 and Thyroid Cancer

WRITTEN BY: Jasper Cantrell

Thyroid cancer is the most common of the endocrine cancers, with papillary thyroid carcinomas (PTCs) being the most common form. Thyroid cancer has excellent diagnostic tools, yet there are still some cases that progress post treatment and a few that are not caught at all. A group from Jeju, South Korea decided to investigate SPARC-related modular calcium-binding protein-2, or SMOC2, as a potential tool for further diagnostic tests to catch recurrence early on.

SMOC2, usually a regulator of a cell’s interaction with the surrounding environment during development or disease, has been implicated in several processes related to the progression of cancer. Using this information, the group began to measure the levels of SMOC2 expression in normal thyroid tissue versus PTC thyroid tissues.

The group began by using reverse transcription PCR to measure the mRNA encoding SMOC2 in normal thyroid tissue against several forms of thyroid cancer. They found that SMOC2 expression was lower in almost every cancer sample compared to normal thyroid samples. Next, they took a large sample size of 338 PTC samples and directly stained for SMOC2. The results, showing a significantly lower level of SMOC2 in PTC samples compared to regular thyroid samples, which concurred with the previous mRNA measurements.

Unfortunately, not every result was as clear cut. The thyroid cancer nodular hyperplasia did not follow the same trend rest of the thyroid cancers, retaining normal levels of SMOC2 expression. Follicular adenomas also failed to produce statistically significant data in SMOC2 expression testing. The group tried to investigate why SMOC2 would be down regulated in PTCs, looking at epigenetic methylation of SMOC2's DNA. The sample sized proved to be to small however, and again could not produce much statistically significant data.

The group concludes “Our findings of SMOC2 expression down-regulation in PTC and its association with improved clinical outcomes clearly suggest that SMOC2 likely acts as a tumor suppressor in thyroid cancers.”. Even though some of the results proved inconclusive, the work done here showed productive insights for the possible use of SMOC2 as a secondary biomarker in tests against thyroid cancer.

Sources: Nature, OncLive

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
MAR 13, 2020
Cancer
MAR 13, 2020
To lower HPV infections, vaccinate boys, too
Past studies and a strategy put forth by the WHO have predicted that it is possible to eradicate cervical cancer within ...
MAR 31, 2020
Cancer
MAR 31, 2020
Ovarian cancer metastasis and CPT1A
Research published in the journal Molecular Cancer Research from collaborators at the University of Colorado C ...
APR 22, 2020
Cancer
APR 22, 2020
This model predicts those at high risk of pancreatic cancer
A new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Can ...
APR 28, 2020
Cancer
APR 28, 2020
Is a multi-cancer detection blood test safe for women?
Earlier detection is essential in order to reduce deaths caused by cancer. A new study, DETECT-A (Detecting cancers Earl ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 13, 2020
Cell & Molecular Biology
MAY 13, 2020
Combined with Fasting-Mimicking Diet, Vitamin C May Have Anti-Cancer Effect
People have long been searching for natural ways to treat cancer in an effort to avoid some of the harmful side effects ...
Loading Comments...